Clinical trials: Pregnancy, Multiple
Chronic Kidney Disease
A Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease
The purpose of this study is to determine the efficacy of chitosan chewing gum (K2CG) in reducing serum phosphorus in subjects with chronic kidney disease.
- Trial name
- NCT01475760
- Testing
- K2CG chewing gum (20mg chitosan), K2CG chewing gum (60mg chitosan)
- Where
- 4 sites in United States
- Volunteers
- 167 people
- Sponsor
- Denver Nephrologists, P.C.
Chronic Kidney Disease, Hyperphosphatemia Undergoing Hemodialysis
Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan
The objective of this study is to assess PK, safety and tolerability of a single oral dose of ASP3325 and to assess PD, PK and safety of repeated oral doses of ASP3325 administered t.i.d. before or just after each meal
- Trial name
- NCT02510274
- Testing
- ASP3325
- Where
- 5 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Inc
Urinary Bladder, Overactive, Incontinence, Urge
Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A
Currently, in clinical practice there has been no standardization in the number of injections a single dose of intradetrusor onabotulinumtoxin A is administered in.
- Conditions
- Urinary Bladder, Overactive, Incontinence, Urge, Incontinence, Urinary, Urinary Urge Incontinence
- Trial name
- NCT04305743
- Testing
- OnabotulinumtoxinA 100 UNT
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of South Florida
Pregnancy Complication, Aortic Dissection
PregnAncy-Related Aortic DISsEction in China
A multicenter observational study on pregnancy-related aortic dissection
- Conditions
- Pregnancy Complication, Aortic Dissection, Marfan Syndrome, Loeys-Dietz Syndrome
- Trial name
- PARADISE (NCT07672210)
- Testing
- Intervention strategies including medication or surgery
- Where
- 4 sites in China
- Volunteers
- 500 people
- Sponsor
- DeltaHealth Hospital · Shanghai
Renal Cell Carcinoma
Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
Multi-Center Randomized Open-Label Study of single agent IMO-2055 Patients who have Metastatic or Locally Recurrent Clear Cell Renal Carcinoma (RCC)
- Trial name
- NCT00729053
- Testing
- IMO-2055
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Lupus Nephritis
Long-Term Study of Multi-target Therapy as Maintenance Treatment for Lupus Nephritis
An multi-site, randomized, prospective study to compare the efficacy and safety of multi-target therapy as continuous induction and maintenance treatment versus CTX- Aza therapy.
- Trial name
- NCT01056237
- Testing
- Multi-target therapy, Azathioprine
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Zhi-Hong Liu, M.D.
End-Stage Renal Disease, End-Stage Kidney Disease
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD) participants receiving hemodialysis via an…
- Conditions
- End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
- Trial name
- NCT05027074
- Testing
- MK-2060
- Where
- 120 sites in United States, Argentina and 13 more
- Volunteers
- 506 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Stones
RETRO Study (RETrograde Renal Access Outcomes)
The goal of this observational study is to learn about the benefit of using RetroPerc® in obtaining renal access for percutaneous nephrolithotomy.
- Trial name
- NCT07071831
- Testing
- RetroPerc®
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of Kansas Medical Center
IgA Nephropathy, CKD Associated With Type 1 Diabetes
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes…
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Trial name
- PHOENIX (NCT03366337)
- Testing
- Bardoxolone methyl capsules
- Where
- 30 sites in United States
- Volunteers
- 103 people
- Sponsor
- Biogen
Cognitive Impairment, RRSO
IMProving Executive Function Study
This is a double-blind, placebo-controlled, crossover study testing whether Vyvanse (lisdexamfetamine; LDX) improves executive functioning (EF) in 100 postmenopausal women who report onset of EF difficulties after oophorectomy.
- Trial name
- IMPRES (NCT03187353)
- Testing
- Lisdexamfetamine
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Kidney Neoplasms, Neoplasm Metastasis
A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer
Bolus PSC 833 is administered on Day 1 simultaneously with initiation of 24 hour continuous infusion of PSC 833, followed by another continuous infusion lasting an additional 6 days.
- Trial name
- NCT00001570
- Testing
- PSC 833, vinblastine
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Pregnant Women, Prenatal Care
MatErnal BLood IS Source to Accurately Diagnose Fetal Aneuploidy
The primary objective of this study is to determine the performance characteristics (sensitivity and specificity) of the Verinata Health Test to detect fetal Trisomy 21 (T21) compared to karyotype results obtained by…
- Trial name
- MELISSA (NCT01122524)
- Where
- 11 sites in United States
- Volunteers
- 10,000 people
- Sponsor
- Verinata Health, Inc.
Smith-Lemli-Opitz Syndrome, Pregnancy
Prenatal Screening For Smith-Lemli-Opitz Syndrome
Smith-Lemli-Opitz Syndrome (SLOS) is a genetic condition that causes mental retardation and other birth defects. This study will evaluate a new prenatal screening test for SLOS.
- Trial name
- NCT00070850
- Where
- United States
- Volunteers
- 1,800 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Chronic Renal Failure, Chronic Kidney Disease
Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With Chronic Kidney Diseases Not on Dialysis
The purpose of this study is to evaluate the safety,efficacy， pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of EPO-018B in participants with chronic kidney disease (CKD) Who are not on dialysis
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Trial name
- NCT02403362
- Testing
- EPO-018B
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Primary Ovarian Insufficiency
Establishing the Diagnosis Standard and Analysis the Risk Factors of POI in Chinese Women
The study aims to establishing the diagnosis standard of POI and analyzing the risk factors in Chinese women.
- Trial name
- NCT03518918
- Where
- China
- Volunteers
- 50,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Lung Cancer, Breast Cancer
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches.
- Conditions
- Lung Cancer, Breast Cancer, Colorectal Cancer, Thyroid Cancer
- Trial name
- NCT06363123
- Where
- 4 sites in China
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Chronic Kidney Disease, Hyperphosphatemia
A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia
This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, randomised, parallel group, flexible dose, the third period is a…
- Trial name
- NCT00416520
- Testing
- MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®), Another phosphate binder (Sevelamer)
- Where
- 68 sites in Australia, Austria and 9 more
- Volunteers
- 336 people
- Sponsor
- Tanabe Pharma Corporation
Pertussis/Whooping Cough
The Optimal Timing of Vaccination in Pregnancy
The central aim of this study is to investigate the optimal timing of vaccination in pregnant women. Therefore, pregnant women will be vaccinated against pertussis at different timepoints and blood and breast milk samples will be…
- Trial name
- MATIMMUNE (NCT06466629)
- Testing
- Triaxis, Sanofi Pasteur
- Where
- Belgium
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Elke Leuridan, MD, PhD
Fraser Syndrome, Fryns Syndrome
Genetic Analysis of Fraser Syndrome and Fryns Syndrome
This study will examine blood or other tissue samples from patients with Fraser syndrome and patients with Fryns syndrome to try to identify the gene responsible for these diseases.
- Conditions
- Fraser Syndrome, Fryns Syndrome, Chromosomal Abnormalities, Abnormalities, Multiple
- Trial name
- NCT00032877
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
End Stage Renal Disease (ESRD)
Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients
In maintenance hemodialysis patients, regular administration of parenteral iron by addition of soluble ferric pyrophosphate (SFP) to the dialysate, when compared to conventional dialysate, is effective in preventing the…
- Trial name
- NCT00604565
- Testing
- soluble ferric pyrophosphate (SFP)
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Charles Drew University of Medicine and Science
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.